



UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS Using real-world evidence to inform valuebased contract (VBC) design for cell and gene therapies (CGTs) Antal Zemplenyi, PhD Visiting Scholar

## Acknowledgements and disclosures

PharmacoEconomics (2024) 42:319-328 https://doi.org/10.1007/s40273-023-01335-x

ORIGINAL RESEARCH ARTICLE



Using Real-World Data to Inform Value-Based Contracts for Cel	
and Gene Therapies in Medicaid	

Antal Zemplenyi<sup>1,2</sup> · Jim Leonard<sup>3</sup> · Michael J. DiStefano<sup>1</sup> · Kelly E. Anderson<sup>1</sup> · Garth C. Wright<sup>1</sup> · Nicholas D. Mendola<sup>1</sup> · Kavita Nair<sup>1</sup> · R. Brett McQueen<sup>1</sup>

Accepted: 2 November 2023 / Published online: 21 November 2023 © The Author(s) 2023



• The University of Colorado is funded by the Department of Health Care Policy & Financing for the assessment of value-based contracts.



## Hemophilia gene therapies

#### Valoctocogene roxaparvovec (Roctavian)

- for severe hemophilia A in adults
- list price \$2.9 million
- Etranacogene dezaparvovec (Hemgenix)
  - for moderate and severe hemophilia B in adults
  - list price \$3.5 million



## Unique challenges in paying for cell and gene therapies (CGTs)

 Known uncertainties including cost offsets and health gains for patients on CGTs





Under-discussed sources of uncertainty for developing value-based contracts (VBCs)\*

- Identification of patients whose mean costs are representative of the SoC costs of the target group for gene therapies.
  - How does eligibility definition affect cost projections for SoC, impacting potential cost offsets and break-even scenarios with CGTs?
- Heterogeneity in real-world standard of care (SoC) costs:
  - How do actual payer costs compare to the cost estimates based on recommended medication usage in clinical guidelines?

\*Other terms used include outcomes-based agreements (OBAs), performance-based risk sharing agreements (PBRS), and managed entry schemes.



### Case study objectives

- Use Colorado Medicaid claims data to reveal
  - Distribution of costs paid by Medicaid
  - Relationship between: eligibility SoC costs breakeven
  - Study period: 2018-2022
- Combine data with "what-if" scenarios to inform
  - Negotiations on contract time horizon in relation to payback amounts
  - Eligibility criteria



# Prevalence of severe hemophilia without inhibitors in adults

Disease	Prevalence per 100 000 males*	Without inhibitors**	Est. patients in Colorado***
Hemophilia A	6.0	87.20%	118
Hemophilia B	1.1	90.90%	23

\*Source: lorio et al. (2019), https://doi.org/10.7326/M19-1208

\*\* Source: Wight J, Paisley S. (2003) <u>https://doi.org/10.1046/j.1365-2516.2003.00780.x</u>, Male et al. (2021) <u>https://doi.org/10.3324/haematol.2019.239160</u> \*\* Based on a total adult population of 4,460,441, of which 50.7% were male in 2021. Source: State Demography Office, CO, https://demography.dola.colorado.gov/



## Assumptions on eligibility

Target population for hemophilia gene therapies: Diagnosed adult patients on prophylactic treatments

Proxies of severity:

Hemophilia A: ≥6 claims/year for factor VIII therapies or Emicizumab → severe Hemophilia B: ≥4 claims/year for factor IX therapies → moderate and severe

Additional eligibility scenarios tested:

Various scenarios explored using claim thresholds between  $\geq$ 4 and  $\geq$ 20 per year



# Highlights of cost analysis methods applicable to RWE

- Factor claims treated as distinct if filed on different days
- Excluded zero-cost factor claims for dual-eligible Medicare-Medicaid patients
- Patients meeting criteria in a year are retained throughout observation
- Factor therapies are the focus, as they account for 95% of the total cost.
- Costs in 2022 US dollars

 $\rightarrow$ Mean costs and SD were inputs in a model-based simulation over a 12-year horizon



## Recent (literature-based) estimates of SoC annual costs in economic evaluation



Hemophilia A factor VIII & emicizumab market basket ~\$640,000

#### Hemophilia B factor IX market basket ~\$690,000

Tice JA, Walton S, Herce-Hagiwara B, Fahim SM, Moradi A, Sarker J, Chu J, Agboola F, Pearson SD, Rind DM. Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A: Effectiveness and Value; Evidence Report. Institute for Clinical and Economic Review, December 22, 2022. https://icer.org/assessment/hemophilia-a-and-b-2022/

Skaggs School of Pharmacy and Pharmaceutical Sciences UNVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS


## Actual cost of SoC

Cohort	Ν	Mean age (SD)	Mean annual cost (SD)
Hemophilia A			
Patients with claims	238	40.4 (16.6)	\$105,000 (\$246,000)
Patients with Factor VIII or Emicizumab utilization	59	34.3 (14.8)	\$298,000 (\$338,000)
Patients on prophylaxis (>=6 relevant claims per year)	36	30.8 (12.3)	\$426,000 (\$353,000)
Hemophilia B			
Patients with claims	54	36.8 (12.9)	\$151,000 (\$353,000)
Patients with Factor IX utilization	<30	33.5 (12.9)	\$301,000 (\$451,000)
Patients on prophylaxis (>=4 relevant claims per year)	<30	30.6 (12.8)	\$546,000 (\$542,000)

Hemophilia A: literature-based cost (\$640,000) was only representative of the top 5% of all patients Hemophilia B: literature-based cost (\$690,000) was representative of the top 13% of all patients



# Cumulative cost difference of Roctavian vs standard care in Hemophilia A




Skaggs School

ANSCHUTZ MEDICAL CAMPUS

Break-even reached in 8 years vs. literature suggesting 4 years

# Cumulative cost difference of Hemgenix vs standard care in Hemophilia B



Skaggs School of Pharmacy and Pharmaceutical Sciences

## Variation in eligibility and financial outcomes: Hemophilia A, Roctavian

Eligibility	Reaching	Balance		Probability of breakeven	
claims per year	break-even (years)	5 years 10 years		5 years	10 years
≥4	10	-\$1,048,548	\$187,315	18%	40%
≥5	9	-\$941,415	\$373,983	22%	45%
≥6 (base case)	8	-\$880,280	\$480,506	23%	48%
≥7	8	-\$828,862	\$570,098	25%	50%
≥8	7	-\$663,862	\$857,594	29%	55%
≥9	7	-\$479,092	\$1,179,540	30%	58%
≥10	6	-\$371,746	\$1,366,580	33%	60%
≥15	5	\$204,654	\$2,370,904	45%	77%
≥20	4	\$1,682,565	\$4,946,028	81%	97%



## Variation in eligibility and financial outcomes: Hemophilia B, Hemgenix

Eligibility	Reaching	Balan	се	Probability of breakeven	
claims per year	break-even (years)	5 years 10 years		5 years	10 years
≥4 (base case)	6	-\$428,742	\$2,490,018	32%	59%
≥5	6	-\$428,742	\$2,490,018	32%	60%
≥6	6	-\$12,407	\$3,299,490	38%	70%
≥7	5	\$123,867	\$3,564,444	42%	71%
≥8	4	\$918,720	\$5,109,862	57%	87%
≥9	4	\$1,199,590	\$5,655,952	61%	90%
≥10	4	\$1,199,590	\$5,655,952	60%	91%
≥15	3	\$3,450,253	\$10,031,870	99%	100%
≥20	3	\$3,981,483	\$11,064,729	100%	100%



### Limitations

- Data is specific to Colorado.
- Analysis did not consider loss to follow-up.
- The number of factor claims may not accurately represent prophylactic therapy utilization



## Key findings

- Actual data may yield substantially different break-even time estimates compared to those derived from published clinical trials and evaluations
- Estimated costs, cost-offsets, and break-even times are contingent upon treatment eligibility criteria, including factor utilization, which is a proxy for prophylaxis and disease severity



## Key takeaways

 Incorporating real-world data into the design of VBCs for CGTs can provide Medicaid agencies with a more accurate understanding of budget projections for CGTs



- Inform negotiations by trading off higher (lower) payback amounts with shorter (longer) contract durations evaluated at varying levels of eligibility
- Leverage improves if Medicaid negotiates as a group of states

